Diligence memo · auto-generated · as of July 2, 2026

Redwood Bioscience Inc

Redwood Bioscience Inc looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Redwood Bioscience Inc operates in Biotechnology, based in EMERYVILLE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Redwood Bioscience Inc has raised $12M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $8.6M on 2013-04-08.

Most recent recorded round closed around 2014-01-16.

Valuation (modeled)modeled

Provath models Redwood Bioscience Inc at approximately $90M (range $2.7M–$491M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.57× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 21 months.

Last raise 12.5 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 3.5× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 59% of Biotechnology peers (4293 compared).

Modeled value ranks above 57% of those peers.

Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc..

Peoplefiled

14 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.